The company has 2 API numbers and one preparation number, and * * * has four production workshops. The main products are gliclazide, metformin hydrochloride, isosorbide mononitrate, isosorbide nitrate, isoflurane, ropivacaine hydrochloride, clarithromycin lactobionate, fluoxetine hydrochloride and lansoprazole. The products have obtained domestic GMP certificate, international top-level certified EU CEP certificate, and passed international official certifications such as FDA, Canada, Japan and South Korea.
The company has a perfect production and R&D system, is a provincial enterprise technology center and a municipal postdoctoral innovation practice base, and has a professional and international R&D team. In March 216, Keyuan Pharmaceutical was successfully listed on the national share transfer system for small and medium-sized enterprises (stock code: 836262), which broadened the company's diversified financing channels.
The company has 9 patents, including 3 invention patents and 6 utility model patents. In 218, it cooperated with East China University of Science and Technology in Industry-University-Research.
At present, gliclazide, isosorbide mononitrate, isosorbide nitrate and ropivacaine hydrochloride account for 65% of the domestic market respectively. Isoprenaline hydrochloride and clarithromycin lactobionate are exclusive varieties in China; At present, the major domestic customers are Meidakang, Shijiazhuang Siyao, Jiuzhoutong, Qilu Pharmaceutical, Shengjitang, Unacon and so on. 3% of the company's products are exported to the international market, and the products are mainly sold to the United States, Canada, Japan, South Korea and other regions.
At present, the company is building a comprehensive API production project, and the main products are ropivacaine hydrochloride, lansoprazole, fluoxetine hydrochloride, isoprenaline hydrochloride, ethamsylate, chlorzoxazone, lurasidone hydrochloride and OR1154.
The future development of the enterprise will focus on taking metformin as the strategic product of Keyuan Pharmaceutical, and realize the leading position of metformin in the global market segment in the next five years. In 22, Keyuan Pharmaceutical will continue to increase R&D investment, introduce new products, and improve the source power of enterprises, with a budgeted output value of 388 million yuan.